Utrophin-Modulating Compounds for Duchenne Muscular Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Duchenne muscular dystrophy face challenges such as immunological responses, toxicity, and delivery issues with gene and cell-based therapies, while pharmacological approaches have shown limited effectiveness in treating the disease.
Innovation Solution
Development of specific compounds that upregulate endogenous utrophin levels, which are administered to patients to treat Duchenne muscular dystrophy, utilizing compounds that modulate utrophin expression to restore dystrophin-associated protein complex function and improve muscle function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy approaches are used to deliver the dystrophin gene, then the missing gene can be replaced, but immunological responses against viral vectors and newly synthesized dystrophin occur along with toxicity and delivery difficulties
Solution Approach 1:
The patent uses utrophin as an intermediary protein to compensate for dystrophin deficiency. Instead of directly delivering the dystrophin gene (which triggers immune responses), the invention delivers a dystrophin-minicircle vector that induces utrophin expression. Utrophin serves as a functional substitute that can restore muscle membrane integrity without triggering the same immunological responses against dystrophin itself.
Solution Approach 2:
The patent changes the therapeutic parameter from delivering dystrophin directly to delivering a minicircle vector that expresses utrophin. This parameter change - switching from dystrophin gene delivery to utrophin-inducing vector delivery - avoids the immunological problems while achieving the same functional outcome of restoring the dystrophin-associated protein complex at the muscle membrane.
2Reliability
If cell therapy approaches are used to deliver dystrophin, then the missing protein can be supplied, but stability of expression and delivery difficulty arise
Solution Approach 1:
The patent extracts the essential therapeutic function (restoring muscle membrane integrity) from the complex cell therapy approach. Instead of using whole cells that require complex delivery and show variable expression stability, the invention extracts and delivers only the genetic instruction (dystrophin-minicircle vector) that can induce utrophin expression in the patient's own muscle cells, achieving stable expression through the patient's own cellular machinery.
3Ease of operation
If pharmacological approaches are used to improve phenotype by decreasing inflammation or improving calcium homeostasis, then muscle function can be improved, but effectiveness in treating DMD remains limited
Solution Approach 1:
The patent takes preliminary action by delivering the dystrophin-minicircle vector before significant muscle damage and fibrosis occur. By establishing utrophin expression early in the disease course, the therapy prevents the development of severe dystrophic pathology rather than attempting to reverse established damage, which explains why pharmacological approaches targeting inflammation or calcium have limited effectiveness in later stages.
Data Source
Figure 1~2
Figure 3~4
AI summary
There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.